Ascletis announces the combination of asc47 and asc31, its dual glp-1r/gipr peptide agonist, demonstrated significantly greater weight loss compared to the combination of asc47 and tirzepatide in an animal model of obesity

-  combination of a low dose of asc47 with asc31, a novel peptide agonist targeting both glp-1 receptor ( glp-1r ) and gip receptor ( gipr ) , resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (dio) mouse model. -  combination of a low dose of asc47 with asc31 demonstrated statistically significantly greater efficacy than a combination of a low dose of asc47 with tirzepatide, 44.8% compared to 38.1%, respectively, in the dio mouse model.
ASC Ratings Summary
ASC Quant Ranking